Back to top

Our Leaders

Principal Investigator - Lisa M. Guay-Woodford, MD 

Dr. Lisa M. Guay-Woodford is the Hudson Professor of Pediatrics at Children's National, a pediatric nephrologist, and an internationally-recognized investigator whose research focuses on identifying clinical and genetic factors involved in the pathogenesis of inherited renal disorders, most notably autosomal recessive polycystic kidney disease (ARPKD). Her research program has been funded by the NIH, the Burroughs Wellcome Fund Clinical Scientist Award in Translational Research, and the Polycystic Kidney Disease Foundation. In 2009, Dr. Guay-Woodford was awarded the Lillian Jean Kaplan International Prize for Advancement in the Understanding of Polycystic Kidney Disease, given by the PKD Foundation and the International Society of Nephrology.

In addition to her clinical and investigative work, Dr. Guay-Woodford is a leader in promoting clinical and translational science. In 2005, she established the UAB Hepato-Renal Fibrocystic Disease Research and Translational Core Center, funded by a NIDDK P30 award. She served as Center Director from 2005 to 2012. Since moving to Children's National in 2012, she has continued to serve as Center co-Director. In 2008, Dr. Guay-Woodford was the founding Director of the UAB Center for Clinical and Translational Science, funded by the NIH CTSA program. Currently, she is the Director of the Children's National Center for Translational Science, as well as Director of the Clinical and Translational Science Institute at Children’s National (CTSI-CN), which is also funded by the NIH CTSA program.

Co-Principal Investigator - Mitchell R. Smith, MD, PhD

Dr. Mitchell R. Smith joined the GWU Cancer Center in Washington DC in 2017 as Associate Cancer Center Director for Clinical Investigations, as well as Chief of the Division of Oncology & Blood Disorders. Until January 2017, Dr. Smith served as the Director of the Lymphoid Malignancy Program at the Cleveland Clinic. After serving as Assistant Professor in Medical Oncology at Wayne State University in Detroit, MI, he joined Fox Chase Cancer Center in 1993, where he remained as Director of the Lymphoma Program until 2012.  His clinical and laboratory interests have focused on targeted approaches to improve therapy of lymphoid malignancies. Dr. Smith is an active member of the ASCO, AACR, ASH and ECOG. He has served on the NCCN lymphoma and myeloma guideline committees, and chaired the Mantle Cell Lymphoma subcommittee of the NCTN lymphoma planning committee.